Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February 2011 and as of October 2014 Crucell is changing its identity into Janssen. For Janssen, the acquisition of Crucell has provided a firm foothold in the increasingly important field of disease prevention. Ultimately, this should mean that many more people around the world can live longer, healthier lives—and we are passionately committed to making that happen.